Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-nectin-4 antibody-drug conjugate LY4052031

An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the cell surface adhesion molecule and tumor-associated antigen (TAA) nectin-4 (PVRL4) conjugated, via a cleavable peptide linker, to the camptothecin analog and topoisomerase 1 inhibitor LSN3889710, with potential antineoplastic activity. Upon administration of the anti-nectin-4 ADC LY4052031, the anti-nectin-4 antibody moiety targets and binds to nectin-4 expressed on tumor cells. Upon binding, internalization and linker cleavage, LSN3889710 is released. LSN3889710 inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of nectin-4-expressing tumor cells. Nectin-4, an immunoglobulin-like protein belonging to the nectin family, is overexpressed in a variety of cancers.
Synonym:anti-nectin-4 ADC LY4052031
anti-nectin-4/LSN3889710 ADC LY4052031
anti-nectin-4/LSN3889710 antibody-drug conjugate LY4052031
Code name:LY 4052031
LY-4052031
LY4052031
Search NCI's Drug Dictionary